Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90

Centre Hospitalier Universitaire Dijon44 enrolled

Overview

NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL). The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Acute T Lymphoblastic Leukemia (T-ALL)Acute B Lymphoblastic Leukemia (B-ALL)

Interventions

injection of BEP 800DRUG

injection of BEP 800

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient suffering from acute lymphoblastic leukaemia whose biological samples are kept at the Biology Technical Platform. Exclusion Criteria: * Patient over 80 years of age

Outcomes

Primary Outcomes

Viability on primary ALL samples

The effect of BEP-800 after 48 hours of treatment on T-ALL and B-ALL will be evaluated by counting viable cells by flow cytometry with a viability marker and specific antibodies to detect leukemia cells.

Time frame: 2 years

Secondary Outcomes

Effect on SRC phosphorylation

The effect of BEP-800 on T-ALL and B-ALL will be evaluated by flow cytometry by measuring HSP90 and SRC (phosphorylated), by intracellular labeling after permeabilization of the cells, 18 hours after treatment with BEP-800.

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.